| Literature DB >> 27048885 |
Giuseppe Lippi1, Fabian Sanchis-Gomar2, Emmanuel J Favaloro3.
Abstract
Despite direct oral anticoagulants becoming a mainstay of anticoagulant therapy, the effective, timely, and safe reversal of their anticoagulant effect remains challenging. Emerging evidence attests that andexanet, a recombinant and inactive variant of native factor X (FXa), competitively inhibits and counteracts the anticoagulant effect of many inhibitors of native activated FXa.Entities:
Keywords: Anticoagulants; andexanet; antidote; apixaban; rivaroxaban
Mesh:
Substances:
Year: 2016 PMID: 27048885 DOI: 10.1016/j.tips.2016.03.002
Source DB: PubMed Journal: Trends Pharmacol Sci ISSN: 0165-6147 Impact factor: 14.819